ORILISSA

This brand name is authorized in Canada, Israel, United States

Active ingredients

The drug ORILISSA contains one active pharmaceutical ingredient (API):

1 Elagolix UNII 5948VUI423 - ELAGOLIX SODIUM

Elagolix is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of elagolix results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone. Read about Elagolix

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ORILISSA Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G03XA	Antigonadotropins and similar agents	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03X Other sex hormones and modulators of the genital system
Discover more medicines within G03XA
H01CC03		H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01C Hypothalamic hormones → H01CC Anti-gonadotropin-releasing hormones
Discover more medicines within H01CC03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02481332, 02481340
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8780, 8781
Country: US	FDA, National Drug Code	Identifier(s): 0074-0038, 0074-0039